The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Spinal Cord Injury Therapeutic Market Research Report 2025
Synopsis
Spinal cord injuries (SCI) are the injuries caused to the thirty one pairs of spinal nerves, which carry nerve signals from brain to various parts of the body and also controls the arm and leg movements. The main cause of spinal cord injuries include trauma, loss of blood supply to spinal cord, and compression in spinal cord due to tumor or infections. Spinal cord injuries can be diagnosed with the help of various techniques such as X-ray, magnetic resonance index (MRI), and computed tomography (CT).
Global Spinal Cord Injury Therapeutic market is projected to reach US$ 2115.6 million in 2029, increasing from US$ 1433 million in 2022, with the CAGR of 6.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Spinal Cord Injury Therapeutic market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Spinal Cord Injury Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Teva Pharmaceutical Industries Ltd.
AbbVie Inc.
Pfizer Inc.
Kringle Pharma, Inc.
Acorda Therapeutics, Inc.
Bioaxone Biosciences, Inc.
RespireRx Pharmaceuticals Inc.
NervGen
Rising Pharmaceuticals, Inc.
Segment by Type
Oral
Intravenously
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Spinal Cord Injury Therapeutic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Spinal cord injuries (SCI) are the injuries caused to the thirty one pairs of spinal nerves, which carry nerve signals from brain to various parts of the body and also controls the arm and leg movements. The main cause of spinal cord injuries include trauma, loss of blood supply to spinal cord, and compression in spinal cord due to tumor or infections. Spinal cord injuries can be diagnosed with the help of various techniques such as X-ray, magnetic resonance index (MRI), and computed tomography (CT).
Global Spinal Cord Injury Therapeutic market is projected to reach US$ 2115.6 million in 2029, increasing from US$ 1433 million in 2022, with the CAGR of 6.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Spinal Cord Injury Therapeutic market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Spinal Cord Injury Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Teva Pharmaceutical Industries Ltd.
AbbVie Inc.
Pfizer Inc.
Kringle Pharma, Inc.
Acorda Therapeutics, Inc.
Bioaxone Biosciences, Inc.
RespireRx Pharmaceuticals Inc.
NervGen
Rising Pharmaceuticals, Inc.
Segment by Type
Oral
Intravenously
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Spinal Cord Injury Therapeutic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Spinal Cord Injury Therapeutic Market Overview
1.1 Product Overview and Scope of Spinal Cord Injury Therapeutic
1.2 Spinal Cord Injury Therapeutic Segment by Type
1.2.1 Global Spinal Cord Injury Therapeutic Market Value Comparison by Type (2023-2029)
1.2.2 Oral
1.2.3 Intravenously
1.3 Spinal Cord Injury Therapeutic Segment by Application
1.3.1 Global Spinal Cord Injury Therapeutic Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Spinal Cord Injury Therapeutic Market Size Estimates and Forecasts
1.4.1 Global Spinal Cord Injury Therapeutic Revenue 2018-2029
1.4.2 Global Spinal Cord Injury Therapeutic Sales 2018-2029
1.4.3 Global Spinal Cord Injury Therapeutic Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Spinal Cord Injury Therapeutic Market Competition by Manufacturers
2.1 Global Spinal Cord Injury Therapeutic Sales Market Share by Manufacturers (2018-2023)
2.2 Global Spinal Cord Injury Therapeutic Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Spinal Cord Injury Therapeutic Average Price by Manufacturers (2018-2023)
2.4 Global Spinal Cord Injury Therapeutic Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Spinal Cord Injury Therapeutic, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Spinal Cord Injury Therapeutic, Product Type & Application
2.7 Spinal Cord Injury Therapeutic Market Competitive Situation and Trends
2.7.1 Spinal Cord Injury Therapeutic Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Spinal Cord Injury Therapeutic Players Market Share by Revenue
2.7.3 Global Spinal Cord Injury Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Spinal Cord Injury Therapeutic Retrospective Market Scenario by Region
3.1 Global Spinal Cord Injury Therapeutic Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Spinal Cord Injury Therapeutic Global Spinal Cord Injury Therapeutic Sales by Region: 2018-2029
3.2.1 Global Spinal Cord Injury Therapeutic Sales by Region: 2018-2023
3.2.2 Global Spinal Cord Injury Therapeutic Sales by Region: 2024-2029
3.3 Global Spinal Cord Injury Therapeutic Global Spinal Cord Injury Therapeutic Revenue by Region: 2018-2029
3.3.1 Global Spinal Cord Injury Therapeutic Revenue by Region: 2018-2023
3.3.2 Global Spinal Cord Injury Therapeutic Revenue by Region: 2024-2029
3.4 North America Spinal Cord Injury Therapeutic Market Facts & Figures by Country
3.4.1 North America Spinal Cord Injury Therapeutic Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Spinal Cord Injury Therapeutic Sales by Country (2018-2029)
3.4.3 North America Spinal Cord Injury Therapeutic Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Spinal Cord Injury Therapeutic Market Facts & Figures by Country
3.5.1 Europe Spinal Cord Injury Therapeutic Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Spinal Cord Injury Therapeutic Sales by Country (2018-2029)
3.5.3 Europe Spinal Cord Injury Therapeutic Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Spinal Cord Injury Therapeutic Market Facts & Figures by Country
3.6.1 Asia Pacific Spinal Cord Injury Therapeutic Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Spinal Cord Injury Therapeutic Sales by Country (2018-2029)
3.6.3 Asia Pacific Spinal Cord Injury Therapeutic Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Spinal Cord Injury Therapeutic Market Facts & Figures by Country
3.7.1 Latin America Spinal Cord Injury Therapeutic Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Spinal Cord Injury Therapeutic Sales by Country (2018-2029)
3.7.3 Latin America Spinal Cord Injury Therapeutic Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Spinal Cord Injury Therapeutic Market Facts & Figures by Country
3.8.1 Middle East and Africa Spinal Cord Injury Therapeutic Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Spinal Cord Injury Therapeutic Sales by Country (2018-2029)
3.8.3 Middle East and Africa Spinal Cord Injury Therapeutic Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Spinal Cord Injury Therapeutic Sales by Type (2018-2029)
4.1.1 Global Spinal Cord Injury Therapeutic Sales by Type (2018-2023)
4.1.2 Global Spinal Cord Injury Therapeutic Sales by Type (2024-2029)
4.1.3 Global Spinal Cord Injury Therapeutic Sales Market Share by Type (2018-2029)
4.2 Global Spinal Cord Injury Therapeutic Revenue by Type (2018-2029)
4.2.1 Global Spinal Cord Injury Therapeutic Revenue by Type (2018-2023)
4.2.2 Global Spinal Cord Injury Therapeutic Revenue by Type (2024-2029)
4.2.3 Global Spinal Cord Injury Therapeutic Revenue Market Share by Type (2018-2029)
4.3 Global Spinal Cord Injury Therapeutic Price by Type (2018-2029)
5 Segment by Application
5.1 Global Spinal Cord Injury Therapeutic Sales by Application (2018-2029)
5.1.1 Global Spinal Cord Injury Therapeutic Sales by Application (2018-2023)
5.1.2 Global Spinal Cord Injury Therapeutic Sales by Application (2024-2029)
5.1.3 Global Spinal Cord Injury Therapeutic Sales Market Share by Application (2018-2029)
5.2 Global Spinal Cord Injury Therapeutic Revenue by Application (2018-2029)
5.2.1 Global Spinal Cord Injury Therapeutic Revenue by Application (2018-2023)
5.2.2 Global Spinal Cord Injury Therapeutic Revenue by Application (2024-2029)
5.2.3 Global Spinal Cord Injury Therapeutic Revenue Market Share by Application (2018-2029)
5.3 Global Spinal Cord Injury Therapeutic Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Teva Pharmaceutical Industries Ltd.
6.1.1 Teva Pharmaceutical Industries Ltd. Corporation Information
6.1.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
6.1.3 Teva Pharmaceutical Industries Ltd. Spinal Cord Injury Therapeutic Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Teva Pharmaceutical Industries Ltd. Spinal Cord Injury Therapeutic Product Portfolio
6.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.2 AbbVie Inc.
6.2.1 AbbVie Inc. Corporation Information
6.2.2 AbbVie Inc. Description and Business Overview
6.2.3 AbbVie Inc. Spinal Cord Injury Therapeutic Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AbbVie Inc. Spinal Cord Injury Therapeutic Product Portfolio
6.2.5 AbbVie Inc. Recent Developments/Updates
6.3 Pfizer Inc.
6.3.1 Pfizer Inc. Corporation Information
6.3.2 Pfizer Inc. Description and Business Overview
6.3.3 Pfizer Inc. Spinal Cord Injury Therapeutic Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer Inc. Spinal Cord Injury Therapeutic Product Portfolio
6.3.5 Pfizer Inc. Recent Developments/Updates
6.4 Kringle Pharma, Inc.
6.4.1 Kringle Pharma, Inc. Corporation Information
6.4.2 Kringle Pharma, Inc. Description and Business Overview
6.4.3 Kringle Pharma, Inc. Spinal Cord Injury Therapeutic Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kringle Pharma, Inc. Spinal Cord Injury Therapeutic Product Portfolio
6.4.5 Kringle Pharma, Inc. Recent Developments/Updates
6.5 Acorda Therapeutics, Inc.
6.5.1 Acorda Therapeutics, Inc. Corporation Information
6.5.2 Acorda Therapeutics, Inc. Description and Business Overview
6.5.3 Acorda Therapeutics, Inc. Spinal Cord Injury Therapeutic Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Acorda Therapeutics, Inc. Spinal Cord Injury Therapeutic Product Portfolio
6.5.5 Acorda Therapeutics, Inc. Recent Developments/Updates
6.6 Bioaxone Biosciences, Inc.
6.6.1 Bioaxone Biosciences, Inc. Corporation Information
6.6.2 Bioaxone Biosciences, Inc. Description and Business Overview
6.6.3 Bioaxone Biosciences, Inc. Spinal Cord Injury Therapeutic Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bioaxone Biosciences, Inc. Spinal Cord Injury Therapeutic Product Portfolio
6.6.5 Bioaxone Biosciences, Inc. Recent Developments/Updates
6.7 RespireRx Pharmaceuticals Inc.
6.6.1 RespireRx Pharmaceuticals Inc. Corporation Information
6.6.2 RespireRx Pharmaceuticals Inc. Description and Business Overview
6.6.3 RespireRx Pharmaceuticals Inc. Spinal Cord Injury Therapeutic Sales, Revenue and Gross Margin (2018-2023)
6.4.4 RespireRx Pharmaceuticals Inc. Spinal Cord Injury Therapeutic Product Portfolio
6.7.5 RespireRx Pharmaceuticals Inc. Recent Developments/Updates
6.8 NervGen
6.8.1 NervGen Corporation Information
6.8.2 NervGen Description and Business Overview
6.8.3 NervGen Spinal Cord Injury Therapeutic Sales, Revenue and Gross Margin (2018-2023)
6.8.4 NervGen Spinal Cord Injury Therapeutic Product Portfolio
6.8.5 NervGen Recent Developments/Updates
6.9 Rising Pharmaceuticals, Inc.
6.9.1 Rising Pharmaceuticals, Inc. Corporation Information
6.9.2 Rising Pharmaceuticals, Inc. Description and Business Overview
6.9.3 Rising Pharmaceuticals, Inc. Spinal Cord Injury Therapeutic Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Rising Pharmaceuticals, Inc. Spinal Cord Injury Therapeutic Product Portfolio
6.9.5 Rising Pharmaceuticals, Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Spinal Cord Injury Therapeutic Industry Chain Analysis
7.2 Spinal Cord Injury Therapeutic Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Spinal Cord Injury Therapeutic Production Mode & Process
7.4 Spinal Cord Injury Therapeutic Sales and Marketing
7.4.1 Spinal Cord Injury Therapeutic Sales Channels
7.4.2 Spinal Cord Injury Therapeutic Distributors
7.5 Spinal Cord Injury Therapeutic Customers
8 Spinal Cord Injury Therapeutic Market Dynamics
8.1 Spinal Cord Injury Therapeutic Industry Trends
8.2 Spinal Cord Injury Therapeutic Market Drivers
8.3 Spinal Cord Injury Therapeutic Market Challenges
8.4 Spinal Cord Injury Therapeutic Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
